HomeMBIO • NASDAQ
add
Mustang Bio Inc
Previous close
$0.21
Day range
$0.20 - $0.21
Year range
$0.13 - $1.68
Market cap
7.56M USD
Avg Volume
3.33M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.46M | -87.50% |
Net income | -1.41M | 85.98% |
Net profit margin | — | — |
Earnings per share | -0.04 | 97.14% |
EBITDA | -1.41M | 87.64% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.52M | -63.14% |
Total assets | 7.19M | -65.03% |
Total liabilities | 15.85M | -4.28% |
Total equity | -8.66M | — |
Shares outstanding | 47.72M | — |
Price to book | -0.90 | — |
Return on assets | -46.37% | — |
Return on capital | 48.83% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -1.41M | 85.98% |
Cash from operations | -1.76M | 85.39% |
Cash from investing | — | — |
Cash from financing | 1.01M | 305.60% |
Net change in cash | -743.00K | 87.24% |
Free cash flow | -1.20M | 51.19% |
About
Mustang Bio is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency. Wikipedia
Founded
2015
Headquarters
Website
Employees
80
